EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+15.71%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$5.92B
AUM Growth
+$5.92B
(+8.6%)
Cap. Flow
+$4.27M
Cap. Flow
% of AUM
0.07%
Top 10 Holdings %
Top 10 Hldgs %
26.27%
Holding
165
New
16
Increased
58
Reduced
30
Closed
23
Top Buys
| 1 |
Zentalis Pharmaceuticals
ZNTL
|
$103M |
| 2 |
Guardant Health
GH
|
$76.4M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
$36.2M |
| 4 |
Toast
TOST
|
$36.2M |
| 5 |
Lithia Motors
LAD
|
$36.1M |
Top Sells
| 1 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$71.9M |
| 2 |
Doximity
DOCS
|
$46M |
| 3 |
Palo Alto Networks
PANW
|
$38M |
| 4 |
Enphase Energy
ENPH
|
$36M |
| 5 |
Roper Technologies
ROP
|
$33.6M |
Sector Composition
| 1 | Healthcare | 43.76% |
| 2 | Technology | 24.19% |
| 3 | Industrials | 13.17% |
| 4 | Consumer Discretionary | 7.97% |
| 5 | Utilities | 3.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Amylyx Pharmaceuticals
AMLX
$892M
| $24.1M | 0.41% |
1,116,837
+658,783
| +144% | +$14.2M |
|
77
Prologis
PLD
$104B
| $23.6M | 0.4% |
192,408
-25,808
| -12% | -$3.16M |
|
78
Keros Therapeutics
KROS
$651M
| $23.3M | 0.39% |
580,000
+280,000
| +93% | +$11.3M |
|
79
Novanta
NOVT
$4.01B
| $23.2M | 0.39% |
126,017
+63
| +0.1% | +$11.6K |
|
80
Clearway Energy Class C
CWEN
$3.38B
| $22M | 0.37% |
771,386
-525,338
| -41% | -$15M |
|
|
MRTX
81
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $21.7M | 0.37% |
600,000
+228,898
| +62% | +$8.27M |
|
82
Arthur J. Gallagher & Co
AJG
$78.1B
| $21.4M | 0.36% |
97,599
-22,159
| -19% | -$4.87M |
|
83
Pentair
PNR
$17.4B
| $21.3M | 0.36% |
330,207
+58,702
| +22% | +$3.79M |
|
84
Intellia Therapeutics
NTLA
$1.32B
| $20.1M | 0.34% |
493,222
| – | – |
|
|
HCP
85
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
| $19.6M | 0.33% |
+749,122
| New | +$19.6M |
|
86
Insmed
INSM
$30.9B
| $19.2M | 0.33% |
912,103
| – | – |
|
87
CMS Energy
CMS
$21.3B
| $18.9M | 0.32% |
321,314
+208,783
| +186% | +$12.3M |
|
88
Veracyte
VCYT
$2.39B
| $18.6M | 0.32% |
732,000
| – | – |
|
89
Cytokinetics
CYTK
$5.95B
| $18.1M | 0.31% |
556,000
| – | – |
|
90
Rocket Pharmaceuticals
RCKT
$364M
| $17.8M | 0.3% |
898,000
| – | – |
|
91
Akero Therapeutics
AKRO
$3.68B
| $17.7M | 0.3% |
379,120
| – | – |
|
92
Alkermes
ALKS
$5.14B
| $17.6M | 0.3% |
+562,233
| New | +$17.6M |
|
93
Roivant Sciences
ROIV
$8.7B
| $17M | 0.29% |
1,690,300
| – | – |
|
94
Repligen
RGEN
$6.76B
| $16.8M | 0.28% |
119,000
| – | – |
|
95
Ultragenyx Pharmaceutical
RARE
$3.14B
| $16.6M | 0.28% |
359,000
| – | – |
|
96
Equity Lifestyle Properties
ELS
$11.5B
| $16.5M | 0.28% |
246,737
| – | – |
|
97
Bruker
BRKR
$4.48B
| $16.3M | 0.28% |
220,803
| – | – |
|
98
BridgeBio Pharma
BBIO
$10B
| $16.2M | 0.27% |
941,176
| – | – |
|
99
Xenon Pharmaceuticals
XENE
$3.06B
| $15.9M | 0.27% |
413,906
-227,294
| -35% | -$8.75M |
|
|
CERE
100
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $15.6M | 0.26% |
490,000
+178,000
| +57% | +$5.66M |
|